JPWO2020033828A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020033828A5 JPWO2020033828A5 JP2021506929A JP2021506929A JPWO2020033828A5 JP WO2020033828 A5 JPWO2020033828 A5 JP WO2020033828A5 JP 2021506929 A JP2021506929 A JP 2021506929A JP 2021506929 A JP2021506929 A JP 2021506929A JP WO2020033828 A5 JPWO2020033828 A5 JP WO2020033828A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- independently selected
- halo
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 48
- 150000001875 compounds Chemical class 0.000 claims 34
- 125000005843 halogen group Chemical group 0.000 claims 31
- 125000003282 alkyl amino group Chemical group 0.000 claims 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims 21
- 125000005842 heteroatoms Chemical group 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- 229910052799 carbon Inorganic materials 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 125000004103 aminoalkyl group Chemical group 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 15
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 14
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 13
- 229910052717 sulfur Inorganic materials 0.000 claims 13
- -1 hydroxy, amino Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 7
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 102100017818 PTPN11 Human genes 0.000 claims 5
- 101710018405 PTPN11 Proteins 0.000 claims 5
- 125000004432 carbon atoms Chemical group C* 0.000 claims 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 125000003368 amide group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 230000001404 mediated Effects 0.000 claims 4
- 229910052698 phosphorus Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 3
- 125000004990 dihydroxyalkyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 208000005101 LEOPARD Syndrome Diseases 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 206010062901 Multiple lentigines syndrome Diseases 0.000 claims 2
- 206010029748 Noonan syndrome Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000005418 aryl aryl group Chemical group 0.000 claims 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Claims (37)
下付き文字のaが0又は1であり、
下付き文字のbが0又は1であり、
Y1が直接的結合又はCR17R18であり、
Y2がC1~4アルキル、アミノ、C1~4アルキルC(O)O-、C1~4アルキルアミノ、及びC1~4アミノアルキルからなる群より選択され、
R1がC6~10アリール、C3~8シクロアルキル、C3~8シクロアルケニル、並びにN、C(O)、O、及びSから独立して選択される1~4個のヘテロ原子又はヘテロ原子群を環員として有する5~10員のヘテロアリール基からなる群より選択され、前記R1のアリール又はヘテロアリールが場合によってはハロ、ヒドロキシ、アミノ、C1~4アルキルアミノ、ジ(C1~4アルキル)アミノ、シアノ、C1~4アルキル、C1~4アルコキシ、C1~4ヒドロキシアルキル、C1~4ハロアルキル、C1~4アミノアルキル、C3~8シクロアルキル、C3~8シクロアルケニル、NR15C(O)R14、NR15C(O)OR14、NR14C(O)NR15R16、NR15S(O)R14、NR15S(O)2R14、C(O)NR15R16、S(O)NR15R16、S(O)2NR15R16、C(O)R14、C(O)OR14、OR14、SR14、S(O)R14、及びS(O)2R14からなる群より独立して選択される1~5個のR12基で置換されており、
R2、R3、R10、及びR11が水素、C1~4アルキル、及びC3~8シクロアルキルからなる群よりそれぞれ独立して選択され、
R4、R5、R8、及びR9が水素、シアノ、C1~4アルキル、C1~4アルコキシ、アミノ、ヒドロキシ、C3~8シクロアルキル、ハロ、及びC1~4アルキルアミノからなる群よりそれぞれ独立して選択され、
R6がアミノ、C1~4アミノアルキル、及びC1~4アルキルアミノからなる群より選択され、
R7が水素、アミド、シアノ、ハロ、及びヒドロキシからなる群より選択され、又はR7がC1~4アルキル、C1~4ヒドロキシアルキル、C3~6シクロアルキル、フェニル、及び5員若しくは6員のヘテロアリールからなる群より選択され、これらのうちのいずれも場合によってはアミノ、ハロ、ヒドロキシ、シアノ、C1~4アルキル、C1~4アルコキシ、C1~4ハロアルキル、C1~4ハロアルコキシ、C1~4アルキルアミノ、及びC1~4アミノアルキルからなる群より独立して選択される1~5個の基で置換されており、
又はR6及びR7が両方とも結合している炭素原子と一緒になってN、C(O)、O、及びS(O)mから独立して選択される0~3個のヘテロ原子又はヘテロ原子群を環員として有する3~7員の飽和環又は不飽和環を形成し、
下付き文字のmが0、1、又は2であり、
R6及びR7によって形成される前記飽和環又は不飽和環が非置換型であるか、又はアミノ、ハロ、ヒドロキシ、シアノ、C1~4アルキル、C1~4アルコキシ、C1~4ハロアルキル、C1~4ハロアルコキシ、C1~4アルキルアミノ、及びC1~4アミノアルキルからなる群より独立して選択される1~3個の基で置換されており、
R2、R3、R4、R5、R7、R8、R9、R10、及びR11のうちのいずれか2個の基がN、O、及びSから選択される0~2個のヘテロ原子を環員として有する5~6員の環を形成してよく、
R2、R4、R6、R8、及びR10のうちのいずれか2個の基が直接的結合、又は1原子若しくは2原子の炭素架橋を形成してよく、
R13が水素、ハロ、シアノ、C1~6アルキル、C1~6ハロアルキル、C1~6ヒドロキシアルキル、C1~6ジヒドロキシアルキル、-NH-NHR19、-NHR19、-OR19、-NHC(O)R19、-NHC(O)NHR19、-NHS(O)2NHR19、-NHS(O)2R19、-C(O)OR19、-C(O)NR19R20、-C(O)NH(CH2)qOH、-C(O)NH(CH2)qR21、-C(O)R21、-NH2、-OH、-S(O)2NR19R20、C3~8シクロアルキル、アリール、N、O、S、及びPから選択される1~5個のヘテロ原子を環員として有するヘテロシクリル、N、O、S、及びPから選択される1~5個のヘテロ原子を環員として有するヘテロアリールからなる群より選択され、前記下付き文字のqが0~6までの整数であり、アリール、ヘテロアリール、ヘテロシクリル、及びシクロアルキルがC1~4アルキル、-OH、-NH2、-OR21、ハロ、シアノ、及びオキソからなる群より独立して選択される0~3個の基で置換されており、
R14、R15、及びR16が水素、C1~4アルキル、C3~8シクロアルキル、C6~10アリール、及び5~10員のヘテロアリールからなる群よりそれぞれ独立して選択され、これらのうちの各々が場合によってはアミド、アミノ、ハロ、ヒドロキシ、シアノ、C1~4アルキル、C1~4アルコキシ、C1~4ハロアルキル、C1~4ハロアルコキシ、C1~4アルキルアミノ、及びC1~4アミノアルキルからなる群より独立して選択される1個以上の基によって置換されており、
R17及びR18が水素、C1~4アルキル、及びCF3からなる群よりそれぞれ独立して選択され、
R19及びR20が水素、C1~6アルキル、C1~6ハロアルキル、C1~6ヒドロキシアルキル、C2~6アルケニル、C2~6アルキニル、及びC3~6シクロアルキルからなる群よりそれぞれ独立して選択され、且つ
各R21が水素、-OH、C1~6アルキル、C1~6ハロアルキル、C1~6ヒドロキシアルキル、C2~6アルケニル、C2~6アルキニル、及びC3~6シクロアルキルからなる群より独立して選択される、
前記化合物、又はその医薬として許容される塩。 Formula I
subscript a is 0 or 1,
subscript b is 0 or 1,
Y1 is a direct bond or CR17R18 ,
Y 2 is selected from the group consisting of C 1-4 alkyl, amino, C 1-4 alkylC(O)O—, C 1-4 alkylamino, and C 1-4 aminoalkyl;
R 1 is C 6-10 aryl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, and 1 to 4 heteroatoms independently selected from N, C(O), O, and S, or is selected from the group consisting of 5- to 10-membered heteroaryl groups having heteroatom groups as ring members, and said aryl or heteroaryl of R 1 is optionally halo, hydroxy, amino, C 1-4 alkylamino, di( C 1-4 alkyl)amino, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 hydroxyalkyl, C 1-4 haloalkyl, C 1-4 aminoalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, NR15C (O)R14, NR15C (O) OR14 , NR14C ( O) NR15R16 , NR15S ( O)R14, NR15S ( O) 2R14 , C(O) NR15R16 , S ( O) NR15R16 , S(O) 2NR15R16 , C ( O) R14 , C ( O) OR14 , OR14 , SR substituted with 1 to 5 R 12 groups independently selected from the group consisting of 14 , S(O)R 14 , and S(O) 2 R 14 ;
R 2 , R 3 , R 10 , and R 11 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, and C 3-8 cycloalkyl;
R 4 , R 5 , R 8 and R 9 are hydrogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl, halo and C 1-4 alkylamino each independently selected from the group of
R 6 is selected from the group consisting of amino, C 1-4 aminoalkyl, and C 1-4 alkylamino;
R 7 is selected from the group consisting of hydrogen, amido, cyano, halo and hydroxy, or R 7 is C 1-4 alkyl, C 1-4 hydroxyalkyl, C 3-6 cycloalkyl, phenyl and 5-membered or is selected from the group consisting of 6-membered heteroaryl any of which optionally amino, halo, hydroxy, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 substituted with 1 to 5 groups independently selected from the group consisting of 4 haloalkoxy, C 1-4 alkylamino, and C 1-4 aminoalkyl;
or 0 to 3 heteroatoms independently selected from N, C(O), O, and S(O) m together with the carbon atom to which R6 and R7 are both attached, or forming a 3- to 7-membered saturated or unsaturated ring having a heteroatom group as a ring member,
subscript m is 0, 1, or 2;
said saturated or unsaturated ring formed by R 6 and R 7 is unsubstituted or amino, halo, hydroxy, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl , C 1-4 haloalkoxy, C 1-4 alkylamino, and C 1-4 aminoalkyl substituted with 1 to 3 groups,
any two of R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 and R 11 are selected from N, O and S 0-2 may form a 5- to 6-membered ring having 1 heteroatom as a ring member,
any two groups of R 2 , R 4 , R 6 , R 8 and R 10 may form a direct bond or a one-atom or two-atom carbon bridge;
R 13 is hydrogen, halo, cyano, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 dihydroxyalkyl, -NH-NHR 19 , -NHR 19 , -OR 19 , - NHC(O)R 19 , —NHC(O)NHR 19 , —NHS(O) 2 NHR 19 , —NHS(O) 2 R 19 , —C(O)OR 19 , —C(O)NR 19 R 20 , —C(O)NH(CH 2 ) q OH, —C(O)NH(CH 2 ) q R 21 , —C(O)R 21 , —NH 2 , —OH, —S(O) 2 NR 19 R 20 , C 3-8 cycloalkyl, aryl, heterocyclyl having 1 to 5 heteroatoms as ring members selected from N, O, S, and P, selected from N, O, S, and P; wherein the subscript q is an integer from 0 to 6, and aryl, heteroaryl, heterocyclyl, and cycloalkyl are C substituted with 0-3 groups independently selected from the group consisting of 1-4 alkyl, —OH, —NH 2 , —OR 21 , halo, cyano, and oxo;
R 14 , R 15 , and R 16 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, C 3-8 cycloalkyl, C 6-10 aryl, and 5-10 membered heteroaryl; each of these is optionally amido, amino, halo, hydroxy, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 alkylamino , and substituted by one or more groups independently selected from the group consisting of C 1-4 aminoalkyl,
R 17 and R 18 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, and CF 3 ;
R 19 and R 20 are from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-6 cycloalkyl; each independently selected and each R 21 is hydrogen, —OH, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C independently selected from the group consisting of 3-6 cycloalkyl,
Said compound, or a pharmaceutically acceptable salt thereof .
下付き文字のbが0又は1であり、
Y1が直接的結合又はCR17R18であり、
Y2がC1~4アルキル、アミノ、C1~4アルキルC(O)O-、C1~4アルキルアミノ、及びC1~4アミノアルキルからなる群より選択され、
R1がC6~10アリール、C3~8シクロアルキル、C3~8シクロアルケニル、並びにN、C(O)、O、及びSから独立して選択される1~4個のヘテロ原子又はヘテロ原子群を環員として有する5~10員のヘテロアリール基からなる群より選択され、前記R1のアリール又はヘテロアリールが場合によってはハロ、ヒドロキシ、アミノ、C1~4アルキルアミノ、ジ(C1~4アルキル)アミノ、シアノ、C1~4アルキル、C1~4アルコキシ、C1~4ヒドロキシアルキル、C1~4ハロアルキル、C1~4アミノアルキル、C3~8シクロアルキル、C3~8シクロアルケニル、NR15C(O)R14、NR15C(O)OR14、NR14C(O)NR15R16、NR15S(O)R14、NR15S(O)2R14、C(O)NR15R16、S(O)NR15R16、S(O)2NR15R16、C(O)R14、C(O)OR14、OR14、SR14、S(O)R14、及びS(O)2R14からなる群より独立して選択される1~5個のR12基で置換されており、
R2、R3、R10、及びR11が水素、C1~4アルキル、及びC3~8シクロアルキルからなる群よりそれぞれ独立して選択され、
R4、R5、R8、及びR9が水素、シアノ、C1~4アルキル、C1~4アルコキシ、アミノ、ヒドロキシ、C3~8シクロアルキル、ハロ、及びC1~4アルキルアミノからなる群よりそれぞれ独立して選択され、
R6がアミノ、C1~4アミノアルキル、及びC1~4アルキルアミノからなる群より選択され、
R7が水素、ハロ、及びヒドロキシからなる群より選択され、又はR7がアミド、C1~4アルキル、C1~4ヒドロキシアルキル、C3~6シクロアルキル、フェニル、及び5員若しくは6員のヘテロアリールからなる群より選択され、これらのうちのいずれも場合によってはアミノ、ハロ、ヒドロキシ、シアノ、C1~4アルキル、C1~4アルコキシ、C1~4ハロアルキル、C1~4ハロアルコキシ、C1~4アルキルアミノ、及びC1~4アミノアルキルからなる群より独立して選択される1~5個の基で置換されており、
又はR6及びR7が両方とも結合している炭素原子と一緒になってN、C(O)、O、及びS(O)mから独立して選択される0~3個のヘテロ原子又はヘテロ原子群を環員として有する3~7員の飽和環又は不飽和環を形成し、
下付き文字のmが0、1、又は2であり、
R6及びR7によって形成される前記飽和環が非置換型であるか、又はアミノ、ハロ、ヒドロキシ、シアノ、C1~4アルキル、C1~4アルコキシ、C1~4ハロアルキル、C1~4ハロアルコキシ、C1~4アルキルアミノ、及びC1~4アミノアルキルからなる群より独立して選択される1~3個の基で置換されており、
R2、R3、R4、R5、R7、R8、R9、R10、及びR11のうちのいずれか2個の基がN、O、及びSから選択される0~2個のヘテロ原子を環員として有する5~6員の環を形成してよく、
R2、R4、R6、R8、及びR10のうちのいずれか2個の基が直接的結合、又は1原子若しくは2原子の炭素架橋を形成してよく、
R13が水素、ハロ、シアノ、C1~6アルキル、C1~6ハロアルキル、C1~6ヒドロキシアルキル、C1~6ジヒドロキシアルキル、-NH-NHR19、-NHR19、-OR19、-NHC(O)R19、-NHC(O)NHR19、-NHS(O)2NHR19、-NHS(O)2R19、-C(O)OR19、-C(O)NR19R20、-C(O)NH(CH2)qOH、-C(O)NH(CH2)qR21、-C(O)R21、-NH2、-OH、-S(O)2NR19R20、C3~8シクロアルキル、アリール、N、O、S、及びPから選択される1~5個のヘテロ原子を環員として有するヘテロシクリル、N、O、S、及びPから選択される1~5個のヘテロ原子を環員として有するヘテロアリールからなる群より選択され、前記下付き文字のqが0~6までの整数であり、アリール、ヘテロアリール、ヘテロシクリル、及びシクロアルキルがC1~4アルキル、-OH、-NH2、-OR21、ハロ、シアノ、及びオキソからなる群より独立して選択される0~3個の基で置換されており、
R14、R15、及びR16が水素、C1~4アルキル、C3~8シクロアルキル、C6~10アリール、及び5~10員のヘテロアリールからなる群よりそれぞれ独立して選択され、これらのうちの各々が場合によってはハロ、ヒドロキシ、シアノ、及びC1~4アルキルからなる群より独立して選択される1個以上の基によって置換されており、
R17及びR18が水素、C1~4アルキル、及びCF3からなる群よりそれぞれ独立して選択され、
R19及びR20が水素、C1~6アルキル、C1~6ハロアルキル、C1~6ヒドロキシアルキル、C2~6アルケニル、C2~6アルキニル、及びC3~6シクロアルキルからなる群よりそれぞれ独立して選択され、且つ
各R21が水素、-OH、C1~6アルキル、C1~6ハロアルキル、C1~6ヒドロキシアルキル、C2~6アルケニル、C2~6アルキニル、及びC3~6シクロアルキルからなる群より独立して選択される、
請求項1に記載の化合物。 subscript a is 0 or 1,
subscript b is 0 or 1,
Y1 is a direct bond or CR17R18 ,
Y 2 is selected from the group consisting of C 1-4 alkyl, amino, C 1-4 alkylC(O)O—, C 1-4 alkylamino, and C 1-4 aminoalkyl;
R 1 is C 6-10 aryl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, and 1 to 4 heteroatoms independently selected from N, C(O), O, and S, or is selected from the group consisting of 5- to 10-membered heteroaryl groups having heteroatom groups as ring members, and said aryl or heteroaryl of R 1 is optionally halo, hydroxy, amino, C 1-4 alkylamino, di( C 1-4 alkyl)amino, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 hydroxyalkyl, C 1-4 haloalkyl, C 1-4 aminoalkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, NR15C (O)R14, NR15C (O) OR14 , NR14C ( O) NR15R16 , NR15S ( O)R14, NR15S ( O) 2R14 , C(O) NR15R16 , S ( O) NR15R16 , S ( O) 2NR15R16 , C ( O) R14 , C ( O) OR14 , OR14 , SR substituted with 1 to 5 R 12 groups independently selected from the group consisting of 14 , S(O)R 14 , and S(O) 2 R 14 ;
R 2 , R 3 , R 10 , and R 11 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, and C 3-8 cycloalkyl;
R 4 , R 5 , R 8 and R 9 are hydrogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, amino, hydroxy, C 3-8 cycloalkyl, halo and C 1-4 alkylamino each independently selected from the group of
R 6 is selected from the group consisting of amino, C 1-4 aminoalkyl, and C 1-4 alkylamino;
R 7 is selected from the group consisting of hydrogen, halo and hydroxy, or R 7 is amido, C 1-4 alkyl, C 1-4 hydroxyalkyl, C 3-6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl any of which optionally amino, halo, hydroxy, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 halo substituted with 1 to 5 groups independently selected from the group consisting of alkoxy, C 1-4 alkylamino, and C 1-4 aminoalkyl;
or 0 to 3 heteroatoms independently selected from N, C(O), O, and S(O) m together with the carbon atom to which R6 and R7 are both attached, or forming a 3- to 7-membered saturated or unsaturated ring having a heteroatom group as a ring member,
subscript m is 0, 1, or 2;
Said saturated ring formed by R 6 and R 7 is unsubstituted or amino, halo, hydroxy, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 substituted with 1 to 3 groups independently selected from the group consisting of 4 haloalkoxy, C 1-4 alkylamino, and C 1-4 aminoalkyl;
any two of R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 and R 11 are selected from N, O and S 0-2 may form a 5- to 6-membered ring having 1 heteroatom as a ring member,
any two groups of R 2 , R 4 , R 6 , R 8 and R 10 may form a direct bond or a one-atom or two-atom carbon bridge;
R 13 is hydrogen, halo, cyano, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 dihydroxyalkyl, -NH-NHR 19 , -NHR 19 , -OR 19 , - NHC(O)R 19 , —NHC(O)NHR 19 , —NHS(O) 2 NHR 19 , —NHS(O) 2 R 19 , —C(O)OR 19 , —C(O)NR 19 R 20 , —C(O)NH(CH 2 ) q OH, —C(O)NH(CH 2 ) q R 21 , —C(O)R 21 , —NH 2 , —OH, —S(O) 2 NR 19 R 20 , C 3-8 cycloalkyl, aryl, heterocyclyl having 1 to 5 heteroatoms as ring members selected from N, O, S, and P, selected from N, O, S, and P; wherein the subscript q is an integer from 0 to 6, and aryl, heteroaryl, heterocyclyl, and cycloalkyl are C substituted with 0-3 groups independently selected from the group consisting of 1-4 alkyl, —OH, —NH 2 , —OR 21 , halo, cyano, and oxo;
R 14 , R 15 , and R 16 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, C 3-8 cycloalkyl, C 6-10 aryl, and 5-10 membered heteroaryl; each of which is optionally substituted with one or more groups independently selected from the group consisting of halo, hydroxy, cyano, and C1-4 alkyl;
R 17 and R 18 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, and CF 3 ;
R 19 and R 20 are from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C 3-6 cycloalkyl each independently selected and each R 21 is hydrogen, —OH, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C independently selected from the group consisting of 3-6 cycloalkyl,
A compound according to claim 1 .
請求項1に記載の化合物。 R 13 is selected from hydrogen, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, C 1-6 dihydroxyalkyl, C 3-8 cycloalkyl, N, O, and S 3- or 6-membered heterocyclyl having 1 to 3 heteroatoms as ring members, wherein heterocyclyl and cycloalkyl are C 1-4 alkyl, —OH, —NH 2 , —OR 21 , halo, substituted with 0 to 3 groups independently selected from the group consisting of cyano and oxo;
A compound according to claim 1 .
請求項1に記載の化合物。 the group in which R 1 consists of C 6-10 aryl and 5-9 membered heteroaryl groups having 1-4 heteroatoms independently selected from N, C(O), O and S as ring members; and optionally halo, hydroxy, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, cyano, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 hydroxyalkyl , C1-4 haloalkyl, C1-4 aminoalkyl, C3-8 cycloalkyl, C3-8 cycloalkenyl , NR15C ( O)R14, NR15C ( O) OR14 , NR14 C(O) NR15R16 , NR15S (O) R14 , NR15S (O) 2R14 , C ( O) NR15R16 , S ( O) NR15R16 , S ( O) 2NR15R16 , C(O) R14 , C ( O) OR14 , OR14 , SR14 , S ( O) R14 , and S (O)2R14 ; substituted with 1 to 5 R 12 groups
A compound according to claim 1 .
請求項10に記載の化合物。 R 1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms independently selected from N, O and S as ring members, and optionally halo, hydroxy , amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 aminoalkyl, and OR 14 substituted with 1, 2, or 3 R 12 groups independently selected from the group
11. A compound according to claim 10.
R7が水素、アミド、シアノ、ハロ、及びヒドロキシからなる群より選択され、又はR7がC1~4アルキル、C1~4ヒドロキシアルキル、C3~6シクロアルキル、フェニル、及び5員若しくは6員のヘテロアリールからなる群より選択され、これらのうちのいずれも場合によってはアミノ、ハロ、ヒドロキシ、シアノ、トリフルオロメチル、トリフルオロメトキシ、C1~4アルキル、及びC1~4アルコキシからなる群より選択される1個又は2個の基で置換されている、
請求項1に記載の化合物。 R 6 is selected from the group consisting of amino, C 1-4 aminoalkyl, and C 1-4 alkylamino, and R 7 is selected from the group consisting of hydrogen, amido, cyano, halo, and hydroxy, or R 7 is selected from the group consisting of C 1-4 alkyl, C 1-4 hydroxyalkyl, C 3-6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which are optionally amino, substituted with 1 or 2 groups selected from the group consisting of halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, and C 1-4 alkoxy;
A compound according to claim 1 .
R7がヒドロキシ、C1~4アルキル、及びC1~4ヒドロキシアルキルからなる群より選択される、
請求項13に記載の化合物。 R 6 is amino or aminomethyl, and R 7 is selected from the group consisting of hydroxy, C 1-4 alkyl, and C 1-4 hydroxyalkyl;
14. A compound according to claim 13.
請求項1に記載の化合物。 1 to 3 heteroatoms or heteroatoms independently selected from N, C(O), O, and S(O) m together with the carbon atom to which R 6 and R 7 are both attached forming a 3- to 7-membered saturated or unsaturated ring having atomic groups as ring members, optionally amino, halo, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, and forming said saturated or unsaturated ring substituted with one or two groups independently selected from the group consisting of C 1-4 aminoalkyl,
A compound according to claim 1 .
請求項15に記載の化合物。 R 6 and R 7 together with the carbon atoms to which they are both attached form a 4-6 membered saturated ring having 1-3 heteroatoms independently selected from N and O as ring members optionally one or _ forming said saturated ring substituted with two groups;
16. A compound according to claim 15.
請求項1に記載の化合物。 Together with the carbon atom to which R 6 and R 7 are both attached, optionally amino, halo, hydroxy, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylamino, and C 1 . forming a 3- to 7-membered cycloalkyl ring substituted with 1 or 2 groups independently selected from the group consisting of ~4 aminoalkyl;
A compound according to claim 1 .
請求項1に記載の化合物。 R 1 is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, and 1,2,4-triazinyl, and optionally halo, hydroxy, amino, C 1-4 alkylamino, di(C 1 1 , 2 independently selected from the group consisting of -4alkyl)amino, C1-4alkyl , C1-4alkoxy , C1-4haloalkyl , C1-4aminoalkyl, and OR14 ; or substituted with 3 R 12 ,
A compound according to claim 1 .
各R12がハロ、ヒドロキシ、アミノ、C1~4アルキルアミノ、ジ(C1~4アルキル)アミノ、C1~4アルキル、C1~4アルコキシ、C1~4ハロアルキル、C1~4アミノアルキル、及びOR14からなる群より独立して選択される、
請求項1に記載の化合物。 R1 is
each R 12 is halo, hydroxy, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 amino independently selected from the group consisting of alkyl, and OR 14 ;
A compound according to claim 1 .
各R12がハロ、ヒドロキシ、アミノ、C1~4アルキルアミノ、ジ(C1~4アルキル)アミノ、C1~4アルキル、C1~4アルコキシ、C1~4ハロアルキル、及びC1~4アミノアルキルからなる群より独立して選択され、且つ
R14がフェニル、又はN、O、及びSから独立して選択される1~4個のヘテロ原子を環員として有する5~6員のヘテロアリールであり、これらのうちの各々が場合によってはC1~4アルキルアミド、ハロ、ヒドロキシ、シアノ、及びC1~4アルキルからなる群より独立して選択される1個又は2個の基によって置換されている、
請求項1に記載の化合物。 R1 is
each R 12 is halo, hydroxy, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, and C 1-4 5- to 6-membered heteroatoms having 1 to 4 heteroatoms as ring members independently selected from the group consisting of aminoalkyl, and R 14 being independently selected from phenyl, or N, O, and S; aryl, each of which optionally by 1 or 2 groups each independently selected from the group consisting of C 1-4 alkylamido, halo, hydroxy, cyano, and C 1-4 alkyl is replaced,
A compound according to claim 1 .
(b)別の治療薬
を含むPTPN11介在性疾患を治療するための医薬組成物であって、前記組成物が治療を必要とする患者に投与される、前記医薬組成物。 ( a ) a therapeutically effective amount of a compound of claim 1; and ( b ) another therapeutic agent.
A pharmaceutical composition for treating a PTPN11-mediated disease comprising: said composition being administered to a patient in need thereof .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023132960A JP2023144075A (en) | 2018-08-10 | 2023-08-17 | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862717588P | 2018-08-10 | 2018-08-10 | |
US62/717,588 | 2018-08-10 | ||
US201862773921P | 2018-11-30 | 2018-11-30 | |
US62/773,921 | 2018-11-30 | ||
PCT/US2019/045903 WO2020033828A1 (en) | 2018-08-10 | 2019-08-09 | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023132960A Division JP2023144075A (en) | 2018-08-10 | 2023-08-17 | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021534124A JP2021534124A (en) | 2021-12-09 |
JPWO2020033828A5 true JPWO2020033828A5 (en) | 2022-08-18 |
Family
ID=67766350
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021506929A Ceased JP2021534124A (en) | 2018-08-10 | 2019-08-09 | 6- (4-Amino-3-methyl-2-oxa-8-azaspiro [4.5] decane-8-yl) -3- (2,3-dichlorophenyl) as an inhibitor of PTPN11 (SHP2) for the treatment of cancer -2-Methylpyrimidine-4 (3H) -one derivative and related compounds |
JP2023132960A Pending JP2023144075A (en) | 2018-08-10 | 2023-08-17 | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023132960A Pending JP2023144075A (en) | 2018-08-10 | 2023-08-17 | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
Country Status (22)
Country | Link |
---|---|
US (2) | US11104675B2 (en) |
EP (2) | EP3833670B1 (en) |
JP (2) | JP2021534124A (en) |
KR (1) | KR20210043569A (en) |
CN (1) | CN112601750B (en) |
AU (1) | AU2019319971A1 (en) |
BR (1) | BR112021002327A2 (en) |
CA (1) | CA3109181A1 (en) |
CL (1) | CL2021000355A1 (en) |
CO (1) | CO2021003074A2 (en) |
CR (1) | CR20210132A (en) |
DK (1) | DK3833670T3 (en) |
FI (1) | FI3833670T3 (en) |
IL (2) | IL307361A (en) |
LT (1) | LT3833670T (en) |
MX (1) | MX2021001608A (en) |
PE (1) | PE20211050A1 (en) |
PH (1) | PH12021550268A1 (en) |
PT (1) | PT3833670T (en) |
SG (1) | SG11202100199UA (en) |
TW (1) | TWI827646B (en) |
WO (1) | WO2020033828A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (en) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | SHP2 phosphatase inhibitors and methods of use thereof |
EP3630770A1 (en) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
CA3094690A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
KR102611661B1 (en) | 2018-05-02 | 2023-12-08 | 나비레 파르마, 인코퍼레이티드 | Substituted heterocyclic inhibitor of PTPN11 |
JP2021534124A (en) | 2018-08-10 | 2021-12-09 | ナビール ファーマ,インコーポレイティド | 6- (4-Amino-3-methyl-2-oxa-8-azaspiro [4.5] decane-8-yl) -3- (2,3-dichlorophenyl) as an inhibitor of PTPN11 (SHP2) for the treatment of cancer -2-Methylpyrimidine-4 (3H) -one derivative and related compounds |
US20200115389A1 (en) | 2018-09-18 | 2020-04-16 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
CA3135555C (en) | 2019-04-02 | 2023-09-19 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
US11001561B2 (en) | 2019-04-08 | 2021-05-11 | Merck Patent Gmbh | Pyrimidinone derivatives as SHP2 antagonists |
EP4034539A1 (en) | 2019-09-24 | 2022-08-03 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
JP2023500328A (en) | 2019-11-08 | 2023-01-05 | レボリューション メディシンズ インコーポレイテッド | Bicyclic heteroaryl compound and use thereof |
CA3183032A1 (en) | 2020-06-18 | 2021-12-23 | Mallika Singh | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
IL308193A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | Ras inhibitors |
CN117500811A (en) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | Covalent RAS inhibitors and uses thereof |
CN117616031A (en) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | RAS inhibitors for the treatment of cancer |
TW202313041A (en) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor. |
TW202317100A (en) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers |
IL309086A (en) | 2021-09-01 | 2024-02-01 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
TW202342043A (en) | 2021-09-30 | 2023-11-01 | 美商納維爾製藥有限公司 | Combination therapy using a ptpn11 inhibitor and an egfr inhibitor |
TW202339729A (en) | 2021-09-30 | 2023-10-16 | 美商納維爾製藥有限公司 | Combination therapy using a ptpn11 inhibitor and a kras g12c inhibitor |
CA3234528A1 (en) * | 2021-10-06 | 2023-04-13 | Navire Pharma, Inc. | Substituted pyrimidin-4(3h)-ones for use in treating cancer |
AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
TW202404599A (en) * | 2022-04-22 | 2024-02-01 | 美商必治妥美雅史谷比公司 | Combination therapy using substituted pyrimidin-4(3h)-ones and nivolumab |
WO2023205794A1 (en) | 2022-04-22 | 2023-10-26 | Bristol-Myers Squibb Company | Combination therapy using a pyrimidone derivative as ptpn11 inhibitor and a pd-1/pd-l1 inhibitor and its use in the treatment of cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004274403A1 (en) | 2003-09-03 | 2005-03-31 | Aventis Pharmaceuticals Inc. | 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds |
EP1720878A1 (en) | 2004-02-27 | 2006-11-15 | F.Hoffmann-La Roche Ag | Heteroaryl-fused pyrazolo derivatives |
JP4790703B2 (en) | 2004-04-07 | 2011-10-12 | 武田薬品工業株式会社 | Cyclic compounds |
EP1814882A1 (en) | 2004-11-22 | 2007-08-08 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
GB0427604D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
GB0506147D0 (en) | 2005-03-24 | 2005-05-04 | Merck Sharp & Dohme | Therapeutic agents |
US20080153810A1 (en) | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
KR20090110913A (en) * | 2007-02-15 | 2009-10-23 | 노파르티스 아게 | Combination of lbh589 with other therapeutic agents for treating cancer |
EP2350020B1 (en) | 2008-10-03 | 2014-08-13 | Merck Sharp & Dohme Corp. | Spiro-imidazolone derivatives as glucagon receptor antagonists |
JP2010111624A (en) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Indazole derivative having ttk inhibitory action |
KR20110049217A (en) | 2009-11-04 | 2011-05-12 | 다우어드밴스드디스플레이머티리얼 유한회사 | Novel organic electroluminescent compounds and organic electroluminescent device using the same |
JP2011246389A (en) | 2010-05-26 | 2011-12-08 | Oncotherapy Science Ltd | Condensed-ring pyrazole derivative having ttk inhibiting action |
WO2012011592A1 (en) * | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | Heterocyclic compound and application thereof |
WO2012106343A2 (en) | 2011-02-01 | 2012-08-09 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
WO2013052263A2 (en) | 2011-09-16 | 2013-04-11 | Microbiotix, Inc. | Antifungal compounds |
WO2013040527A1 (en) | 2011-09-16 | 2013-03-21 | Microbiotix, Inc. | Antimicrobial compounds |
WO2014047662A2 (en) | 2012-09-24 | 2014-03-27 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
CN110423212B (en) | 2013-04-26 | 2023-05-09 | 美国印第安纳大学研究和技术公司 | Hydroxy indole carboxylic acid-based inhibitors of SHP2 |
EP3003302A4 (en) | 2013-05-24 | 2016-12-14 | Scripps Research Inst | Bidentate-binding modulators of lrrk2 and jnk kinases |
WO2015099481A1 (en) | 2013-12-27 | 2015-07-02 | 주식회사 두산 | Organic electroluminescent device |
US10093646B2 (en) | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
JO3517B1 (en) | 2014-01-17 | 2020-07-05 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
KR101998435B1 (en) | 2014-06-09 | 2019-07-09 | 주식회사 두산 | Organic electro luminescence device |
MX2017000168A (en) * | 2014-07-03 | 2017-05-01 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1. |
KR101708097B1 (en) | 2014-10-22 | 2017-02-17 | 주식회사 두산 | Organic electro luminescence device |
EP3273959A1 (en) | 2015-03-25 | 2018-01-31 | Novartis Ag | Pharmaceutical combinations |
EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
CN112625028A (en) | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | Compounds and compositions for inhibiting SHP2 activity |
US10308660B2 (en) * | 2015-06-19 | 2019-06-04 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
CN107286150B (en) | 2016-04-11 | 2020-07-07 | 中国科学院上海有机化学研究所 | N-heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application |
WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
WO2017211303A1 (en) | 2016-06-07 | 2017-12-14 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
ES2810852T3 (en) | 2016-06-14 | 2021-03-09 | Novartis Ag | Compounds and compositions to inhibit shp2 activity |
MX2019000548A (en) | 2016-07-12 | 2019-10-30 | Revolution Medicines Inc | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors. |
WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (en) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | SHP2 phosphatase inhibitors and methods of use thereof |
EP3568204B1 (en) | 2017-01-10 | 2023-08-30 | Novartis AG | Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor |
AR110740A1 (en) | 2017-01-23 | 2019-05-02 | Revolution Medicines Inc | BICYCLIC COMPOUNDS AS SHP2 ALOSTERIC INHIBITORS |
EP3571189B1 (en) * | 2017-01-23 | 2023-03-29 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
EA202190196A1 (en) | 2017-03-23 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | NEW HETEROCYCLIC DERIVATIVES USED AS SHP2 INHIBITORS |
EP3630770A1 (en) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
EP3678703A1 (en) | 2017-09-07 | 2020-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
JP7447002B2 (en) | 2017-09-11 | 2024-03-11 | クルーゾン・ファーマシューティカルズ・インコーポレイテッド | Octahydrocyclopenta[c]pyrrole allosteric inhibitor of SHP2 |
EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
CA3078565A1 (en) | 2017-10-12 | 2019-04-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
MX2020006273A (en) | 2017-12-15 | 2020-09-14 | Revolution Medicines Inc | Polycyclic compounds as allosteric shp2 inhibitors. |
US11426422B2 (en) | 2018-01-30 | 2022-08-30 | Research Development Foundation | SHP2 inhibitors and methods of use thereof |
MA51845A (en) | 2018-02-13 | 2020-12-23 | Shanghai Blueray Biopharma Co Ltd | CYCLIC COMPOUND MERGED WITH A PYRIMIDINE, ITS PREPARATION PROCESS AND ITS APPLICATION |
EP3755699A1 (en) | 2018-02-21 | 2020-12-30 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
NZ766835A (en) | 2018-03-02 | 2023-09-29 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
KR20200144102A (en) | 2018-03-21 | 2020-12-28 | 신블리아 테라퓨틱스 인코포레이티드 | SHP2 inhibitors and uses thereof |
EP3768680A1 (en) | 2018-03-21 | 2021-01-27 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
CA3094690A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
CA3096535A1 (en) | 2018-04-10 | 2019-10-17 | Revolution Medicines, Inc. | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
KR102611661B1 (en) | 2018-05-02 | 2023-12-08 | 나비레 파르마, 인코퍼레이티드 | Substituted heterocyclic inhibitor of PTPN11 |
CN116003321A (en) | 2018-05-09 | 2023-04-25 | 北京加科思新药研发有限公司 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
US20210230300A1 (en) | 2018-06-04 | 2021-07-29 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
MX2021000795A (en) | 2018-07-24 | 2021-04-12 | Taiho Pharmaceutical Co Ltd | Heterobicyclic compounds for inhibiting the activity of shp2. |
TWI825144B (en) | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | Transglutaminase 2 (tg2) inhibitors |
JP2021534124A (en) | 2018-08-10 | 2021-12-09 | ナビール ファーマ,インコーポレイティド | 6- (4-Amino-3-methyl-2-oxa-8-azaspiro [4.5] decane-8-yl) -3- (2,3-dichlorophenyl) as an inhibitor of PTPN11 (SHP2) for the treatment of cancer -2-Methylpyrimidine-4 (3H) -one derivative and related compounds |
TWI824069B (en) | 2018-11-30 | 2023-12-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | Compounds useful in hiv therapy |
WO2020113213A2 (en) | 2018-11-30 | 2020-06-04 | Comet Therapeutics, Inc. | Cyclic pantetheine derivatives and uses thereof |
AR117183A1 (en) | 2018-11-30 | 2021-07-14 | Syngenta Crop Protection Ag | THIAZOL DERIVATIVES MICROBIOCIDES |
JP7241871B2 (en) | 2018-11-30 | 2023-03-17 | メルク・シャープ・アンド・ドーム・エルエルシー | 9-substituted aminotriazoloquinazoline derivatives, pharmaceutical compositions and their use as adenosine receptor antagonists |
AR117200A1 (en) | 2018-11-30 | 2021-07-21 | Syngenta Participations Ag | THIAZOL DERIVATIVES MICROBIOCIDES |
-
2019
- 2019-08-09 JP JP2021506929A patent/JP2021534124A/en not_active Ceased
- 2019-08-09 AU AU2019319971A patent/AU2019319971A1/en active Pending
- 2019-08-09 LT LTEPPCT/US2019/045903T patent/LT3833670T/en unknown
- 2019-08-09 IL IL307361A patent/IL307361A/en unknown
- 2019-08-09 BR BR112021002327-5A patent/BR112021002327A2/en unknown
- 2019-08-09 SG SG11202100199UA patent/SG11202100199UA/en unknown
- 2019-08-09 FI FIEP19759185.2T patent/FI3833670T3/en active
- 2019-08-09 EP EP19759185.2A patent/EP3833670B1/en active Active
- 2019-08-09 WO PCT/US2019/045903 patent/WO2020033828A1/en active Application Filing
- 2019-08-09 PE PE2021000191A patent/PE20211050A1/en unknown
- 2019-08-09 CN CN201980046071.6A patent/CN112601750B/en active Active
- 2019-08-09 KR KR1020217003134A patent/KR20210043569A/en active IP Right Grant
- 2019-08-09 US US16/536,923 patent/US11104675B2/en active Active
- 2019-08-09 PT PT197591852T patent/PT3833670T/en unknown
- 2019-08-09 MX MX2021001608A patent/MX2021001608A/en unknown
- 2019-08-09 CR CR20210132A patent/CR20210132A/en unknown
- 2019-08-09 EP EP24161326.4A patent/EP4356973A3/en active Pending
- 2019-08-09 CA CA3109181A patent/CA3109181A1/en active Pending
- 2019-08-09 IL IL280701A patent/IL280701B2/en unknown
- 2019-08-09 DK DK19759185.2T patent/DK3833670T3/en active
- 2019-08-12 TW TW108128631A patent/TWI827646B/en active
-
2021
- 2021-02-04 PH PH12021550268A patent/PH12021550268A1/en unknown
- 2021-02-10 CL CL2021000355A patent/CL2021000355A1/en unknown
- 2021-03-09 CO CONC2021/0003074A patent/CO2021003074A2/en unknown
- 2021-07-20 US US17/380,943 patent/US11945815B2/en active Active
-
2023
- 2023-08-17 JP JP2023132960A patent/JP2023144075A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2020033828A5 (en) | ||
JP2019517487A5 (en) | ||
KR101364762B1 (en) | Compounds for the treatment of proliferative disorders | |
JP5149177B2 (en) | Tubulin polymerized 1,2,3-triazole inhibitors for the treatment of proliferative diseases | |
JP2020521740A5 (en) | ||
JP2016506959A5 (en) | ||
JP2012507566A5 (en) | ||
JP2019520417A5 (en) | ||
RU2003132687A (en) | TREATMENT OF TYPE 2 DIABETES BY DIPEPTIDYLPEPTIDASE IV INHIBITORS | |
JP2017528498A5 (en) | ||
RU2007116987A (en) | NEW COMPOUNDS | |
RU2010150786A (en) | Pyrrolopyridines as kinase inhibitors | |
JPWO2020061101A5 (en) | ||
JP2016506962A5 (en) | ||
JP2016526576A5 (en) | ||
JP2004525179A5 (en) | ||
JP2011509309A5 (en) | ||
RU2011121567A (en) | ISOINDOLINE COMPOUNDS FOR USE IN TREATMENT OF CANCER | |
KR940701384A (en) | Azanorbornane derivatives | |
SI3018132T1 (en) | Fused imidazole derivatives useful as ido inhibitors | |
JP2006501202A5 (en) | ||
JP2017526677A5 (en) | ||
RU2012116877A (en) | COMPOUNDS OF 2-PYRIDONE USED AS NEUTROPHIL ELASTASE INHIBITORS | |
CA2550350A1 (en) | 2-(hetero)aryl-substituted tetrahydroquinoline derivatives | |
SI3140296T1 (en) | Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes |